Peer-influenced content. Sources you trust. No registration required. This is HCN.
Multiple Sclerosis News Today
An experimental cell therapy that couples a patient’s red blood cells with myelin protein fragments was well tolerated in a 10-patient Phase 1b study and was associated with increases in regulatory T-cells and reductions in neurofilament light chain, a biomarker linked to nerve injury.
Neuroimmunology September 9th 2026
Renal & Urology News
National Cancer Database data suggest that approximately half of prostate cancer focal therapy use from 2010 to 2023 occurred outside current guideline-supported settings, highlighting persistent gaps between clinical practice and available evidence.
Hematology/Oncology September 3rd 2026
Physician’s Weekly
Tranexamic acid was associated with lower rates of major bleeding among patients undergoing urologic surgery in a prespecified POISE-3 trial analysis, while thrombotic event rates remained similar between treatment groups.
Anesthesiology September 3rd 2026
News Medical
Researchers identified a metabolic pathway in which amino acid breakdown generates propionyl-CoA, sustaining cholesterol production and androgen signaling in prostate cancer models. The findings suggest a potential mechanism of hormone therapy resistance, though clinical relevance remains unproven.
Clinical Pharmacology September 3rd 2026
MDLinx
Double-filtration plasmapheresis reduced circulating concentrations of several PFAS in small patient samples, while microplastic changes varied by polymer. The exploratory findings do not support apheresis for environmental pollutant removal.
Cardiology September 2nd 2026
Healthline
Two phase 3 trials found upadacitinib increased scalp, eyebrow, and eyelash regrowth in adolescents and adults with severe alopecia areata. Longer-term safety, durability, and regulatory review remain important considerations.
Dermatology September 2nd 2026